Clinical Trials

164 enrolled

Cholangiocarcinoma

NCT05101551 2026-04-22

PARPAML

Other hematologic neoplasm

34 enrolled

Leukemia, Myeloid, Acute

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

30 enrolled

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06027268 2026-04-22

ToPCourT

36 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06423326 2026-04-22

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

36 enrolled

Phase 1 Enrolling by invitation

Pancreatic Neoplasms

NCT07353294 2026-04-22

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

12 enrolled

Lymphatic Metastasis

NCT07540390 2026-04-22

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

Phase 3 Not yet recruiting

442 enrolled

Nasopharyngeal Carcinoma

NCT06623656 2026-04-21

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

112 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07158489 2026-04-21

ORIGIN2

47 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04984837 2026-04-20

Study of Lacutamab in Peripheral T-cell Lymphoma

56 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT05632328 2026-04-20

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

24 enrolled

Pancreatic Neoplasms

NCT04158635 2026-04-17

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

21 enrolled

Pancreatic Neoplasms

NCT06492759 2026-04-17

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Phase 1 Active not recruiting

Liver Neoplasms

NCT00479128 2026-04-16

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

80 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

LymphoidOther hematologic neoplasm

80 enrolled

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Hodgkin Disease, Recurrence

NCT04940286 2026-04-16

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

13 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT05497778 2026-04-16

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

19 enrolled

Pancreatic Neoplasms

NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Terminated

5 enrolled 13 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05967182 2026-04-16

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

24 enrolled

Cholangiocarcinoma

NCT07283705 2026-04-16

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

60 enrolled

Phase 2 Study

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

60 enrolled

Carcinoma, Transitional Cell

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

105 enrolled

Phase 1/2 Active not recruiting

Borderline Resectable Pancreatic Adenocarcinoma

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

31 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07020065 2026-04-15

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04577014 2026-04-14

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Phase 1/2 Recruiting

98 enrolled

Sarcoma

NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

240 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

750 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07529483 2026-04-14

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts

35 enrolled

Pancreatic Cystic Neoplasm

NCT03403049 2026-04-13

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Phase 1 Completed

14 enrolled

Neoplasms, Pancreatic Neoplasms

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

237 enrolled

Infiltrating Bladder Urothelial Carcinoma

NCT06454383 2026-04-13

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

19 enrolled

Pancreatic Neoplasms

NCT07325539 2026-04-13

LIGHT

55 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07524413 2026-04-13

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

514 enrolled

Nasopharyngeal Neoplasms

NCT03406299 2026-04-09

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2 Completed

92 enrolled

Biliary Tract Neoplasms

NCT06790602 2026-04-09

SWITCH

43 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

38 enrolled

Pancreatic Adenocarcinoma

NCT06958328 2026-04-08

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT07466238 2026-04-08

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Phase NA Recruiting

40 enrolled

Biliary Tract Neoplasms

NCT01679119 2026-04-07

INCA

Phase 2 Completed

129 enrolled 7 charts

Lymphoma, Large B-Cell, Diffuse

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

32 enrolled

Carcinoma, Transitional Cell

NCT06632327 2026-04-07

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT06639724 2026-04-07

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

36 enrolled

Pancreatic Neoplasms

NCT07000084 2026-04-07

GAIN-BCG

330 enrolled

Phase 2/3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07001618 2026-04-03

IMMUNOLIFE2

162 enrolled